A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK

INTRODUCTION: Once-weekly semaglutide 1 mg is a novel glucagon-like peptide 1 receptor agonist (GLP-1 RA) that, in the SUSTAIN clinical trials, has demonstrated greater reductions in glycated haemoglobin (HbA1c) and body weight than the other GLP-1 RAs exenatide extended-release (ER) 2 mg, dulagluti...

Descripción completa

Detalles Bibliográficos
Autores principales: Johansen, Pierre, Sandberg, Anna, Capehorn, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089718/
https://www.ncbi.nlm.nih.gov/pubmed/32048148
http://dx.doi.org/10.1007/s12325-020-01242-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089718/
https://www.ncbi.nlm.nih.gov/pubmed/32048148
http://dx.doi.org/10.1007/s12325-020-01242-z

Ejemplares similares